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Abstract
Statins such as simvastatin are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors and standard
therapy for the prevention and treatment of cardiovascular diseases in mammals. Here we show that simvastatin
significantly increased the mean and maximum lifespan of Drosophila melanogaster (Drosophila) and enhanced cardiac
function in aging flies by significantly reducing heart arrhythmias and increasing the contraction proportion of the
contraction/relaxation cycle. These results appeared independent of internal changes in ubiquinone or juvenile hormone
levels. Rather, they appeared to involve decreased protein prenylation. Simvastatin decreased the membrane association
(prenylation) of specific small Ras GTPases in mice. Both farnesyl (L744832) and type 1 geranylgeranyl transferase (GGTI-298)
inhibitors increased Drosophila lifespan. These data are the most direct evidence to date that decreased protein prenylation
can increase cardiac health and lifespan in any metazoan species, and may explain the pleiotropic (non-cholesterol related)
health effects of statins.
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Introduction
Cardiovascular disease is the leading cause of morbidity and
mortality worldwide. Statins, which are competitive inhibitors of
HMG-CoA reductase, reduce the biosynthesis of mevalonate.
Mevalonate is a precursor in the synthesis of many different
compounds in mammals, including cholesterol, isoprenoids, and
ubiquinones (Figure 1) [1]. Statins are standard therapies for the
prevention and treatment of hyperlipidemia, hypertension, con-
gestive heart failure, and renal disease [2]. A major part of their
positive effects on cardiovascular disease arises from a reduction in
cholesterol biosynthesis, and an accompanying decrease in plasma
cholesterol levels.
Statins also appear to reduce all-cause mortality in healthy,
normolipidemic adults [3]. Isoprenoids, which are synthesized
downstream of mevalonate, are required for the posttranslational
farnesylation and geranylgeranylation of proteins, especially the
small, signaling Ras GTPases [1,4,5]. Isoprenoid adducts on these
signaling GTPases anchor them to cell membranes, which is
essential to their activity [6,7]. Statins reduce the prenylation of
Ras and Rho in cell culture, leading to the accumulation of their
inactive forms in the cytoplasm [8]. Based mostly on such in vitro
studies, reduced prenylation of these small, monomeric GTP
binding proteins is postulated to be responsible for many of the
non-cholesterol-related health effects of statins [8,9].
Drosophila can be used to study the etiology and treatment of
human diseases (e.g. [10,11]). For example, many of the genetic
and metabolic pathways involved in the development and
functioning of the heart are evolutionarily conserved between flies
and humans [11,12], as are many of the signaling pathways
associated with longevity [13,14]. Insects lack several of the
enzymes required for the de novo biosynthesis of cholesterol [15].
Here, we used Drosophila as a model for studies of the
noncholesterol-related longevity and health effects of statins.
Together our data show, more directly than has been done
previously, that statins extend lifespan and enhance cardiac
function by reducing protein prenylation.
Results
Simvastatin increased Drosophila lifespan
We found that simvastatin dose-responsively increased Drosophila
lifespan by 25% (P,0.0001; Figure 2; Table 1). Two hundred forty
mM simvastatin optimally increased lifespan, while higher or lower
doses were less effective (Table 1). Thus, it appears that partial
inhibition of HMG-CoA reductaseactivity increases Drosophila lifespan.
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consumption (CR) or locomotor activity
Caloric restriction can extend the life- and healthspan of many
metazoans [14]. Modified CAFE assays [16] and assays we termed
‘‘fecal plaque assays’’ (FPAs) [17,18] were used to determine
whether reduced food consumption might be the source of the
longevity effects of simvastatin [19] (see Materials and Methods).
CAFE assays measure the volume of liquid medium consumed
from micropipette ‘‘straws’’. FPAs measure the deposition of fecal
waste in discrete ‘‘plaques’’ on the inner walls of flybottles. Both
assays were utilized because CAFE assays are widely used, while
FPAs are performed under conditions similar to those used for our
lifespan assays. There is a strong correlation between food
consumption data generated by the two assays [20]. Simvastatin
either increased or had no effect on food consumption as
measured by CAFE assays (Table 2). The drug also had no effect
on food consumption as measured by FPAs (Tables 3 and 4).
There was no effect on fecal plaque number or size. Simvastatin
also had no effect on the weight of the flies (Table 5). Thus, the
longevity effects of simvastatin do not involve reduced food intake.
Table 1. Effect of drug treatments on the lifespan of Drosophila in Figures 2, 3, 4.
Lifespan data from Figure 2
Treatment Mean lifespan (days) Standard error
Vehicle 35.1 0.8
Simvastatin (0.024 mM) 36.8 1.0
Simvastatin (0.24 mM) 43.9 1.0
Simvastatin (2.4 mM) 37.7 0.9
Simvastatin (12 mM) 38.3 0.9
Lifespan data from Figure 3
Treatment Mean lifespan (days) Standard error
Vehicle 24.3 0.3
Simvastatin (240 mM ) 25.5 0.3
Methoprene (320 mM ) 25.7 0.4
Simvastatin (240 mM) and methoprene (320 mM) 28.0 0.6
Lifespan data from Figure 4
Treatment Mean lifespan (days) Standard error
Vehicle 26.5 0.4
Simvastatin (240 mM) 29.7 0.4
CoQ10 (5 mM) 24.3 0.5
CoQ10 (5 mM) and simvastatin (240 mM) 28.4 0.5
doi:10.1371/journal.pone.0039581.t001
Figure 1. The acetyl CoA-mevalonate pathway in insects and
mammals. The X at the head of the cholesterol branch of the pathway
indicates that insects lack several enzymes required for cholesterol
biosynthesis.
doi:10.1371/journal.pone.0039581.g001
Figure 2. Simvastatin extends the lifespan of Drosophila.
Simvastatin was fed to the flies in their food beginning on the first
day of eclosure. Shown is survival at zero (#), 0.024 (%), 0.24 (n), 2.4
(,), and 12 (e) mM simvastatin. As judged by the log rank test, the
lifespan of the flies was significantly changed when they were treated
with 24 mM (P=0.047), 240 mM( P ,0.0001), 2.4 mM (P=0.017) and
12 mM (P=0.0004) simvastatin.
doi:10.1371/journal.pone.0039581.g002
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[21]. However, we found no effect of simvastatin on locomotor
activity using an assay which closely recapitulates the conditions of
the lifespan assays (Table 6). Thus, simvastatin extended Drosophila
longevity without the confounding effects of CR or altered
locomotion.
Statins do not extend lifespan reducing juvenile
hormone (JH) signaling
The synthesis of mevalonate from acetyl CoA is irreversible
(Figure 1). Thus, in insects, mevalonate is committed to the
synthesis of non-cholesterol end-products of the isoprenoid
pathway. We were unable to reliably measure JH levels using
liquid chromatography tandem mass spectrometry (LC-MS/MS).
For this reason, we investigated the role of JH signaling in
longevity by treating flies with methoprene, a highly specific,
stable, small molecule JH receptor agonist widely used to prevent
insect molting (Figure 3). Methoprene and simvastatin each
increased lifespan when administered alone, and together their
effects were synergistic (Figure 3; Table 1). These results indicate
that simvastatin does not increase Drosophila lifespan by reducing
JH receptor signaling. Further, because their effects are synergistic
at their optimum dosages, simvastatin and methoprene likely
utilize independent pathways to increase lifespan.
Neither methoprene alone, nor methoprene and simvastatin
together had any significant effect on food consumption as
determined using CAFE assays or FPAs (Tables 2, 3 and 4). In
addition, methoprene had no effect on the weight of the flies
(Table 5). Thus, the longevity effects of methoprene are not due to
induced CR.
Statins do not extend lifespan by reducing endogenous
CoQ10
Because mevalonate is a precursor in ubiquinone biosynthesis
(Figure 1), we investigated whether simvastatin extended lifespan
by reducing endogenous ubiquinone levels. Diets supplemented
with simvastatin and/or ubiquinone were administered to
Drosophila. Supplementation with CoQ10 alone significantly
shortened lifespan, while simvastatin alone significantly lengthened
it (Figure 4; Table 1). CoQ10 and simvastatin together signifi-
cantly lengthened lifespan, although not by as much as simvastatin
alone (Figure 4; Table 1).
Table 2. Food consumption does not change in response to chemical additions to the diet as determined by CAFE assays
analyzed with Tukey’s Multiple Comparison Test
a.
Treatment
Mean
Difference
b Q Summary
c
95% Confidence interval
of difference
Control vs.
simvastatin
20.2868 6.652 ** 20.4678 to 20.1058
Control vs.
methoprene
20.1455 3.374 NS 20.3265 to 0.0356
Control vs.
Methoprene + simvastatin
20.1475 3.421 NS 20.3285 to 0.0336
Simvastatin vs.
methoprene
0.1413 3.278 NS 20.0397 to 0.3224
Simvastatin vs.
methoprene + simvastatin
0.1393 3.231 NS 20.0417 to 0.3204
Methoprene vs.
methoprene + simvastatin
20.0020 0.0467 NS 20.1831 to 0.1790
aSee Materials and Methods for specifics regarding the studies. The fly medium contained either an equal volume of vehicle, 2.4 mM simvastatin, 320 mM methoprene, or
their combination.
bMean difference between food consumption in the absence and presence of the drug(s).
cThe notation ** indicates the difference was highly significant (P#0.01). The notation NS indicates that the results were not significantly different.
doi:10.1371/journal.pone.0039581.t002
Table 3. Food consumption does not change in response to
chemical additions to the diet as determined by both FPA and
CAFE assays.
Treatment
1 FPAs CAFE Assays
Plaque
number/cm
2/fly
(mean ± SD)
Plaque Diameter
(mm)
2
(mean ± SD)
mL
consumed/fly/hr
(mean ± SD)
Control 0.10760.003
a2 0.08960.003
a 0.34360.010
a
Simvastatin 0.10860.008
a 0.09360.003
a 0.47260.026
b
L-774832 0.11260.009
a 0.08660.003
a 0.38660.010
a
GGTI-298 0.10760.005
a 0.09460.003
a 0.47460.049
b
1See Materials and Methods for specifics regarding the studies. The medium
contained either an equal volume of vehicle, 2.4 mM simvastatin, 320 mM
methoprene, 20 mM L744832, or 300 mM GGTI-298.
2Column values with the same superscript letters are not significantly different,
as determined by one way ANOVA followed by Tukey’s multiple comparison
test. Column values with different superscript letters are significantly different
(P#0.05). See Materials and Methods for specifics regarding the studies.
doi:10.1371/journal.pone.0039581.t003
Table 4. Food consumption as measured by FPA does not
change in response to simvastatin or methoprene.
Control
a Simvastatin Methoprene
Simvastatin plus
Methoprene
0.100860.0062
a 0.086860.0135
a 0.128860.0122
a 0.106260.0047
a
aThese data are the means plus or minus the standard error of the plaque
number per cm
2 per fly per hour. The plaque values are not significantly
different as judged by ANOVA followed by Tukey’s multiple comparison test.
See Materials and Methods for specifics regarding the studies.
doi:10.1371/journal.pone.0039581.t004
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might explain the results in Figure 4, we quantified the effects of
the drugs on the endogenous levels of CoQ in Drosophila by LC-
MS/MS. Simvastatin treatment significantly decreased internal
CoQ10 levels by approximately 21% (Figure 5), consistent with
inhibition of mevalonate production (Figure 1). Surprisingly,
supplementation with CoQ10 also significantly decreased internal
CoQ10 levels, in this case to 53% of control levels (Figure 5).
Simvastatin and CoQ10 together decreased internal CoQ levels to
47% of the level in untreated flies.
Therefore, the lifespan effects of simvastatin and CoQ10 do not
correlate with their effects on endogenous CoQ10 levels. These
results strongly indicate that simvastatin does not extend Drosophila
lifespan by decreasing the level of endogenous CoQ10.
Statins decreased the active, farnesylated and
geranylgeranylated forms of specific RAS-related
signaling GTPases
The isoprenoids synthesized from mevalonate are used for the
prenylation of the small Ras-related signaling GTPases. These
modifications are essential for their activity (see Discussion). Statin-
induced changes in the prenylation of these small signaling
proteins are thought to be responsible for the non-cholesterol-
related effects of statins in humans [8], although the vast majority
of the studies supporting this idea have been performed using
cultured cells [8]. Thus, it is still unclear whether changes in
protein prenylation are responsible for the non-cholesterol related
effects of statins on human lifespan.
To investigate this question, we first examined whether statin
treatment of intact animals affected the prenylation, and therefore
the membrane localization of small Ras family GTPases. After
multiple attempts, the antibodies available did not reproducibly
detect these proteins on Western blots of membrane and
cytoplasmic proteins from Drosophila. However, we were able to
detect many of these proteins in liver membrane and cytoplasmic
fractions prepared from statin treated mice. Simvastatin treatment
depleted the active membrane bound form of Rab4 and increased
the level of its inactive cytoplasmic form (Figure 6A and B).
Similarly, simvastatin treatment increased the cytoplasmic level of
inactive Ras by 3.3-fold. The membrane bound form of Ras was
below the level of detection in these studies. In contrast,
simvastatin had no effect on the membrane bound and cytoplas-
mic forms of Rac1/2/3 (data not shown). Importantly, calnexin, a
membrane-specific protein, and a-tubulin, a cytoplasmic protein,
partitioned appropriately during cell fractionation, confirming that
the procedures effectively separated their cellular compartments
(Figure 6A). Together, these results show that simvastatin reduced
the prenylation of specific Ras GTPases in vivo, leading to the
accumulation of their inactive forms in the cytoplasm.
Inhibition of isoprenyl transferases extended Drosophila
lifespan
To investigate whether drug induced reduction in protein
prenylation could be responsible for the increased longevity found
with statins, the effects of specific inhibitors of protein prenylation
on Drosophila lifespan were investigated. Both L744832, a potent
and specific farnesyl transferase inhibitor (Figure 7A), and GGTI-
298, a potent and specific type I geranylgenranyl transferase
inhibitor, significantly increased Drosophila lifespan in a dose-
responsive manner (Figure 7B). Further, neither drug had any
significant effect on food intake as measured by fecal plaque
number and size (Table 3), or fly weight (Table 5). CAFE assays
detected an increase in food consumption with both simvastatin
and GGTI-298 treatments, while L744832 produced no effect
(Table 3). Together these results indicate that the increase in
Table 5. Fly weight in response to drug treatments.
Treatment
1
Weight
2
(mg/10 flies)
Vehicle 8.2260.17
a
Simvastatin 8.2360.05
a
Methoprene 8.0760.11
a
L-774832 8.1260.06
a
GGTI-298 8.0860.09
a
1Newly eclosed Drosophila were maintained for 12 days at 25uC with medium
containing either an equal volume of vehicle, 2.4 mM simvastatin, 320 mM
methoprene, 20 mM L744832, or 300 mM GGTI-298. Groups of 10 flies were
anesthetized with CO2, immediately removed from the flybottles, and weighed
(n=12).
2Column values with the same superscript letters are not significantly different,
as determined by one way ANOVA. See Materials and Methods for specifics
regarding the studies.
doi:10.1371/journal.pone.0039581.t005
Figure 3. Juvenile hormone signaling and simvastatin treat-
ment stimulate lifespan synergistically. Shown are the lifespans of
Drosophila in the absence of drugs [control (#)]; and in the presence of
240 mMs i m v a s t a t i n( %); 320 mM methoprene (n); and 320 mM
methoprene and 240 mM simvastatin together (.). The mean lifespan
of the simvastatin, methoprene, and simvastatin with methoprene
treated flies was significantly increased (P=0.02, P=0.0034, and
P,0.0001, respectively).
doi:10.1371/journal.pone.0039581.g003
Table 6. Locomotor activity of simvastatin treated Drosophila
Treatment1 N Mean±SEM
2 P value
Control 5 15,30262683
Simvastatin 5 15,10563486 P=0.6244
1Groups of 10 newly eclosed Drosophila were maintained for 14 days at 25uC
with medium containing either an equal volume of vehicle or 2.4 mM
simvastatin in a TriKinetics Drosophila Activity Monitoring System.
2Infrared beam disruptions per 24 hours.
doi:10.1371/journal.pone.0039581.t006
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induced CR. Likewise, neither L744832, GGTI-298, nor
simvastatin had any significant effect on the movement of the
flies (Tables 6 and 7). Two independent studies with GGTI-298,
and 4 independent studies with L744832 found no effect on
movement. These results precluding altered locomotor activity as a
source of the longevity effects of the drugs.
The effects of L744832 and GGTI-298 on lifespan were not
additive, and co-treatment with simvastatin did not lead to greater
lifespan extension than treatment with simvastatin alone (data not
shown). These results suggest that simvastatin extends lifespan by
inhibiting farnesylation and geranylgeranylation. The results are
consistent with the apparent increase in human lifespan associated
with statin treatment of healthy, normocholesterolemic adults [3].
Simvastatin decreased arrhythmias in old flies
To investigate the mechanisms for the positive effects of
simvastatin on lifespan, its effects on cardiac function were studied
using 4-week-old flies. Analysis of high speed movies of beating
hearts showed that simvastatin dramatically reduced the overall
incidence of arrhythmias in these old flies (Figure 8). The
arrhythmia index (AI) of 0.39 in untreated 4-week old flies is
similar to that previously reported (Ocorr et al., 2007). However,
simvastatin treatment with the same concentration that extended
lifespan (Figure 2) lowered the AI to half (0.19), which is typical of
young hearts. Simvastatin treatment had no effect on systolic
interval length (0.3060.02 sec for control v. 0.3160.01 sec for
simvastatin, mean 6 SEM, P=0.99 ) nor did it affect the %
fractional shortening (4261% control vs. 4261% simvastatin,
mean 6 SEM, P=0.8 ), which is a measure of heart contractility.
Interestingly, the diastolic interval (DI) length was reduced in the
simvastatin group (1.0160.09 sec for control vs. 0.7960.07 sec for
simvastatin, mean 6 SEM ) but this decrease did not reach
significance (P=0.065). Nevertheless, because the systolic interval
length remained unchanged, this decrease in DI resulted in a
significant increase in the amount of time the heart is contracted
during each contraction/relaxation cycle: 0.2660.02 sec/ heart
period for control vs. 0.360.02 sec/ heart period for simvastatin
treated flies (mean 6 SEM, P=0.035). Thus, the longevity effects
of simvastatin in flies may result from a reduction in arrhythmias
and an increase in the relative time the heart spends in
contraction.
Endogenous simvastatin levels
We hoped to compare the endogenous levels of simvastatin in
flies with that of treated animals. However, repeated attempts to
measure the level of simvastatin in isolated hemolymph and serum
from simvastatin treated mice were unsuccessful using two
established extraction techniques [22,23], and GC-MS/MS
(Materials and Methods). These results were probably due to the
low levels of the drug in the serum and hemolymph, and the
limited quantities of each available. For example, each fly yielded
approximately 0.5 mL of hemolymph.
Statin treatment did not alter stress resistance
In flies and mammals, interventions that extend lifespan often
enhance resistance to various stresses [24–26]. However, we were
unable to detect any effect of simvastatin on resistance to anoxia-
reoxygenation stress or paraquat toxicity using several standard
techniques with either young or old flies (Materials and Methods).
Thus, despite enhancement of cardiac performance and lifespan,
statins do not appear to increase general stress resistance.
Discussion
A number of novel results are presented here. First, we show
that simvastatin extended the lifespan of Drosophila, and increased
cardiac functioning in old flies. Second, we demonstrated that
statin treatment reduced protein prenylation of specific Ras
signaling GTPases in mice. Third, we showed that drugs which
reduce protein prenylation in vivo extend the lifespan of Drosophila.
As a part of these studies, we also showed that juvenile hormone
agonists extend, rather than decrease the lifespan of adult
Drosophila, and that CoQ10 supplementation reduces, rather than
increases, internal CoQ10 levels in Drosophila.
Figure 4. Ubiquinone administration slightly reduces lifespan.
Shown are the lifespan of flies consuming food containing no drugs
[control (#)]; 240 mM simvastatin (%); 5 mM CoQ10 (.); 5 mM CoQ10
and 240 mM simvastatin (N). The mean lifespans of the flies treated with
simvastatin alone (P,0.0001) and with 5 mM CoQ10 plus simvastatin
(P=0.0058) were significantly greater than that of control. The mean
lifespan of the flies treated with 5 mM CoQ10 alone was significantly
less than control (P=0.0001)
doi:10.1371/journal.pone.0039581.g004
Figure 5. Supplementation with simvastatin and CoQ10
reduces endogenous ubiquinone levels. Ubiquinone (5 mM) and
simvastatin (240 mM) administered to Drosophila in their food alone or
together decreased the endogenous levels of CoQ10 as measured by
LC-MS/MS. Two asterisks indicate the differences were highly significant
(P#0.01) and three indicate that the differences were very highly
significant (P#0.001). Sim below a bar indicates the flies were treated
with simvastatin.
doi:10.1371/journal.pone.0039581.g005
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reduced ubiquinone biosynthesis
While simvastatin treatment reduced internal ubiquinone levels,
our data appear to exclude this effect as the mechanism for
increased fly longevity. Dietary CoQ10 actually decreased internal
CoQ10 levels. We can only speculate at this time about the reason
for this effect. Drosophila may have a mechanism for sensing dietary
ubiquinone levels, and downregulating internal levels in response.
Statin treatment is associated with reductions in blood and
tissue ubiquinone levels in statin treated humans, rats, and mice
[27–29]. As mentioned in the introduction, statin treatment also
reduces all-cause mortality in healthy people with no history of
cardiovascular disease [3]. Here we found that these two
phenomena are unrelated in Drosophila. Endogenous reduction in
ubiquinone induced by CoQ10 feeding shortened lifespan, and
may have blunted the beneficial effects of simvastatin on lifespan
(Figs. 5 and 6). Thus, reduced ubiquinone levels do not appear to
contribute to the salutary effects of statins, and may oppose them.
Indeed, feeding Drosophila yeast lacking CoQ reportedly reduces
their lifespan relative to flies fed CoQ replete yeast [30]. In rodents
and C. elegans, most [31–34], although not all [35,36], studies find
that CoQ10 supplementation has no effect on lifespan. Taken
together, the results presented here and published data indicate
that reduced ubiquinone levels are not responsible for the
longevity effects of simvastatin.
JH and lifespan in Drosophila
The administration of methoprene on a wick of paper rescued
the longevity phenotype (reduced the lifespan) of daf-2 mutant
Drosophila [37,38]. Tatar and his colleagues concluded from this
that JH deficiency extends Drosophila longevity. Our studies with
wild type Oregon-R flies found that methoprene in food
reproducibly increased lifespan (Figure 3). The reasons for the
apparent differences in these results are unclear. However, the
data in the Tatar study involved a mutant fly. Our results make it
very unlikely that simvastatin increases the lifespan of wild type
Drosophila by decreasing JH signaling.
Inhibition of protein isoprenylation increases longevity
Ras and Rho farnesylation, and Ras, Rho, and Rab
geranylgeranylation anchor these proteins on the inner side of
the cytoplasmic membrane, where they can interact with
downstream effectors of cytoplasmic signaling networks [6]. Statins
induce cholesterol-independent effects which include enhanced
endothelial function, greater stability of atherosclerotic plaque,
decreased oxidative stress and inflammation, and reduced
Figure 6. Simvastatin administration to mice decreased prenylation of specific small G proteins, as measured by a decrease in their
membrane association. Panel A, Western blot showing the level of Rab4, Ras, calnexin, and a-tubulin in the cytoplasmic and membrane fractions
purified from the liver of control and simvastatin treated mice. Panel B shows the quantification of the data shown in Panel A. The levels of Rab4 in
the cytoplasmic fractions were normalized to the level of a-tubulin in each sample. The levels of Rab 4 in the membrane fractions were normalized to
the level of calnexin in each sample. Means and standard errors obtained with tissue from control (open bars) and simvastatin treated (closed bars)
mice are shown. One of the precipitated membrane samples was overloaded on this blot, and the amount of Rab4 reported in panel B was
determined from another blot. The scanner units were adjusted to facilitate comparisons between membrane and cytoplasmic fractions.
doi:10.1371/journal.pone.0039581.g006
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by inhibition of isoprenoid biosynthesis [8]. The Ras family of
small signaling GTPases are isoprenylated at their C-termini,
which allows them to cycle between a membrane tethered, active
state, and a soluble, inactive state [8,40]. Statin inhibition of
isoprenoid biosynthesis reduces the number of membrane-bound,
active proteins, and increases the pool of soluble, inactive proteins
[8].
Most studies of the effects of statins on protein isoprenylation
have been performed in vitro [8,41]. Our in vivo studies found
that Rab4 and Ras respond to simvastatin treatment by increasing
the level of their inactive, soluble forms (Figure 6). The Rab
GTPases are a family of 63 mammalian proteins which control
secretion, endocytosis, signal transduction and development [42].
Rab4 regulates specific steps in vesicle trafficking and receptor
recycling in early endosomes. Thus, reduced Rab4 activity could
influence the secretion and/or display of other signaling factors
and membrane receptors. The Ras GTPases are a family of 4
proteins which link tyrosine kinase activation at the cell membrane
to growth, differentiation, apoptosis, cytoskeletal organization and
membrane trafficking [43]. Thus, simvastatin may pleiotropically
alter signal transduction by multiple systems. We used geranylger-
anyl and farnesyl transferase inhibitors to show that such effects on
signal transduction can increase lifespan. This is the first
demonstration that these pathways can increase lifespan.
Statin treatment improved cardiac functioning
We showed that simvastatin enhances cardiac functioning in
Drosophila by reducing the age-related increase in arrhythmias
(Figure 8). Simvastatin also increased pumping efficacy by
decreasing the DI and increasing the relative proportion of the
cardiac cycle spent in contraction (Figure 8). These results are
consistent with reports suggesting that statins are antiarrhythmic
and inhibit atrial fibrillation in patients with coronary artery
disease [44,45]. In humans and animal models, statins protect the
myocardium from acute ischemia – reperfusion injury and
increase survival after stroke (reviewed in [46]) These effects are
mediated by inhibition of HMG-CoA reductase activity, but
appear to involve isoprenoid, rather than cholesterol biosynthesis
(reviewed in [47,48]).
Conclusions
We directly showed that statin treatment increased the lifespan
and cardiac health of Drosophila. We also showed that statin
treatment decreased protein isoprenylation. Further, we showed
that decreased protein isoprenylation extended the lifespan of
Drosophila. The linkage between these phenomena indicates that
statins can extend lifespan by decreasing protein prenylation,
which leads to enhanced cardiac health in old age and increased
longevity.
Materials and Methods
Drosophila survival studies
Male flies were used for these studies to avoid the confounds
associated with redirecting metabolic energy from survival to
reproductive behavior. Freshly eclosed flies (Wild-type Oregon-R-
C Drosophila Melanogaster (Bloomington Drosophila Stock Center,
Department of Biology, Indiana University, Bloomington, IN)
were sorted under light CO2 anesthesia, and male flies placed into
8 ounce fly bottles (Genesee Scientific) and covered with
35610 mm Petri dish lids (Falcon) containing ,5.5 ml of
Standard Cornmeal Medium (SCM). The concentrations of drugs
indicated in the figure legends were dissolved in DMSO and 10 ml
applied to the surface of the SCM and spread carefully over the
entire surface. Controls utilized 10 ml of DMSO, spread as
described above. L744832 was from Enzo (catalogue #G-242) and
GGTI-298 from Sigma (catalogue #G5169). Dye studies indicate
that 10 mL of DMSO diffuses to approximately 1 mm depth over
48 hours. Unless otherwise indicated, a total of 4 bottles per drug
concentration, with 50 male flies per bottle (200 flies total) were
used for each determination. The lids were attached to the bottle
opening and secured with tape. The walls of the plastic bottles
were pierced with small air holes. The bottles were incubated with
the lid closures on top (to minimize evaporative drying) at 25uC,
60% humidity, and with a 12 :12 hour light: dark cycle. The
SCM-lids were replaced twice weekly. The number of flies living at
each time point was determined by visual inspection. CO2
anesthesia was not used after the initial sorting of males from
females.
Quantification of food consumption
The capillary feeder (CAFE) assay [16] was modified to use
30 flies in eight ounce plastic fly bottles with four, 100 ml
Figure 7. Inhibition of farnesyl transferase or geranylgeranyl
transferase I activity increases Drosophila lifespan. Shown in
panel A are the lifespans of Drosophila in the absence of drugs [control
(#)]; and in the presence of 5 mM( %); 10 mM( n); or 20 mM( .)
L744832. The mean lifespan of flies treated with 5, 10, and 20 mM
L744832 were significantly increased relative to control (P=0.0089,
P,0.0001, and P=0.0019, respectively). In panel B are shown the
lifespans of Drosophila in the absence of drugs [control (#)]; and in the
presence of 100 mM( n) or 300 mM( .) GGTI-298. The mean lifespan of
flies treated with 100 and 300 mM GGTI-298 was significantly increased
relative to control (P,0.0001 and P,0.0001, respectively).
doi:10.1371/journal.pone.0039581.g007
Table 7. Locomotor activity of L744832 and GGTI-298 treated
Drosophila.
Treatment1 N Mean ± SEM P value
Study 1
Control 4 12,9396692.4
GGTI-298 4 13,54764272 0.8952
Study 2
Control 9 20,38462271
L744832 9 16,96161969 0.2715
1Groups of 10 newly eclosed Drosophila were maintained for 14 days at 25uC
with medium containing either an equal volume of vehicle, 20 mM L744832, or
300 mM GGTI-298 in a Drosophila Activity Monitoring System.
doi:10.1371/journal.pone.0039581.t007
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5% autolyzed yeast extract (Fisher Scientific, Pittsburgh, PA),
and 0.01% (v/v) DMSO either alone (control) or containing the
concentration of drug indicated in the text. A small amount of
r e df o o dc o l o r i n gw a sa d d e dt of a c i l i t a t em e a s u r e m e n t s .T h e
cotton bottle closures were saturated with 25 ml of reverse
osmosis, nano-pure water (Barnstead, Inc.), to maintain humid-
ity during the 24 hour incubation at 25uC. Food intake was also
measured using FPAs. The standard SCM with agar in Petri
dish lids were prepared as described. One-half ml of SCM
without agar was mixed with 10 mlo fD M S Ow i t h o u t( c o n t r o l )
or with 10 ml of the indicated concentration of drug and one
drop of red food color, and evenly spread over the surface of an
SCM lid. The lids were used to feed bottles of 50 flies for
24 hours. After removal of the lids and the flies, 5, 464c m
square regions were randomly marked on the side of each bottle,
and the numbers of red feces dots (plaques) counted. Four
bottles were used per control or treatment group. To determine
plaque sizes, fly bottles from FPAs were positioned under a
Celestron Handheld Digital Microscope, Model #44302-A, and
their diameter determined using the software provided (n=40
for each condition). The mean number of plaques per square
centimeter and plaque diameter was compared by t-test or one
way ANOVA using GraphPad Prism.
Quantitation of locomotor activity
Drosophila movement was quantified using a Trikinetics
Drosophila Activity Monitoring System and DAMSystem data
acquisition software package sold with the unit. The system
records the number of disruptions of three infrared beams by
moving flies. Drug treatment was begun immediately after
eclosure. After 14 days of treatment, the number of disruptions
caused by 10 flies was recorded continuously for three days. The
total number of disruptions of the beams per 24 hours is reported.
Drosophila cardiac function
Male flies were collected at eclosion and aged for 4 weeks at
25
oC on SCM in the presence or absence of 240 mM simvastatin,
as described above. Heart physiology in flies was assessed using a
semi-intact adult fly preparation combined with a semiautomated
optical heartbeat analysis program that quantifies heartbeat
parameters including diastolic and systolic diameters, heart period
and rate, heart beat regularity and fractional shortening [49,50].
In addition, the arrhythmia index, a measure of heartbeat
regularity, is calculated from high-speed digital movies using the
mean standard deviation of the heart period normalized to the
median heart period. M-modes, a qualitative record showing heart
edge movement over time, were also produced using the optical
heartbeat analysis program [50].
Figure 8. Simvastatin administration reduces the number of old flies that exhibit severe arrhythmias, as quantified by the AI, a
measure of heartbeat regularity. Panel A shows a summary of the results showing that AI is significantly reduced in hearts from 4 week old flies
fed simvastatin compared to vehicle (n=35 flies for each group; p,0.05, as judged by an unpaired t-test). Panel B, the number of simvastatin and
vehicle treated flies exhibiting each arrhythmia index is shown. Panel C, examples of M-mode intervals representing different arrhythmicity indices.
doi:10.1371/journal.pone.0039581.g008
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and Ras
Male C3B6F1 mice were maintained and drug treated as
described [19]. Liver tissue from 18 month-old control and
simvastatin treated mice (188 mg/kg diet) was snap frozen and
stored in liquid nitrogen. Forty mg of tissue was powdered under
liquid nitrogen with a mortar and pestle. Soluble and membrane
bound proteins were prepared using a ProteoJET Membrane
Protein Extraction Kit (www.fermentas.com) as described by the
supplier, except that the Cell Permeabilization and Membrane
Protein Extraction Buffers contained protease inhibitor cocktail
(10 ml per ml; Sigma). Western blots were performed using
standard procedures, and immobilized proteins were visualized
using IgG against a-tubulin, Rac1/2/3, Rab4, and Ras from Cell
Signaling, and antibody against calnexin and goat anti-rabbit IgG
conjugated to horseradish peroxidase from Abcam.
LC-MS/MS analysis of endogenous CoQ10
Samples were prepared as described [23]. Briefly, 300 to 400
flies were homogenized with 1 ml of water and 50 mL of 10 mg/
ml ethanolic butylated hydroxytoluene using an Ultra-Turrax
homogenizer (Tekmar Company). The homogenate was mixed
with 1 ml of 0.1M aqueous SDS, and 2 ml of reagent alcohol and
vortexed for 30 s. The mixture was combined with 2 ml of hexane
and vigorously vortexed for 2 min followed by 5 min centrifuga-
tion at 10006g. One ml of the hexane layer was transferred to a
small vial and dried under argon. A working solution of 800 mg/
mL CoQ10 (Cat # C9538, Sigma-Aldrich, St. Louis, MO) in
hexane and an internal standard solution of 600 mg/mL CoQ6
(Cat # 900150-0 from Avanti Polar Lipid, Inc., Alabaster, AL) in
ethanol were prepared. CoQ10 calibration solutions were
prepared at 0, 0.025, 0.05, 0.1, 0.5, 1, 2, 20, 150, and 500 mg/
mL by serial dilution of the CoQ10 working solution with 50%
ethanol. Each dilution was spiked with CoQ6 internal standard to
a final concentration of 6 mg/mL. LC-MS/MS analysis was
performed on an Agilent 6510 Q-TOF system coupled with an
Agilent HPLC-Chip Cube MS interface (Agilent Technologies,
Santa Clara, CA). Sample injection, enrichment, desalting, and
HPLC separation were carried out on the Agilent HPLC Chip
with an integrated trapping column (160 nL) and a separation
column (Zorbax 300SB-C18, 75 mm 6150 mm, 5 mm in particle
size). The samples were first loaded onto a trapping column with a
solvent mixture of 2-propanol (HPLC grade)/methanol (HPLC
grade)/formic acid (Fisher Scientific) (55:45:0.05, v/v) with
5 mmol/L methylamine at a flow rate of 2.8 mL/min (Agilent
1200 series capillary pump). The analytes were separated
isocratically using the same mobile phase at a flow rate of 300
nL/min. The Chip spray voltage was set as 1950 V and varied
depending on the chip conditions. The temperature and flow rate
of the drying gas were 325uC and 4 L/min. Nitrogen was the
collision gas. The collision energy followed the equation with a
slope of 3 V/100 Da and an offset of 2.5 V. MS/MS experiments
were carried out by monitoring the fragmentations of the
methylammonium adduct ([M+CH3NH3]
+) of the analyte and
internal standard molecules. A calibration curve for CoQ10
quantification was constructed by plotting the ratios of areas of
peaks found in the selected-ion chromatograms for monitoring the
transitions of CoQ10 (m/z 894.740 197.075) over CoQ6 (m/z
622.483 197.075) versus the molar ratios of CoQ10 over CoQ6.
The amount of CoQ10 in the samples were subsequently
determined from the peak area ratios found in the selected-ion
chromatograms for the same transitions of CoQ10 over CoQ6, the
calibration curve, and the amount of CoQ6 spiked into the
samples.
LC-MS/MS quantification of simvastatin in serum and
hemolymph
Two methods were utilized for sample preparation for LC-MS/
MS analysis. In the first, 200 mL of serum from a simvastatin-
treated mouse, or hemolymph from 70 simvastatin-treated flies
extracted into a final volume of 200 mL with PBS, were spiked
with an internal standard of 1.8 nmol of lovastatin, and extracted
as described [22]. Briefly, the samples were mixed with 120 mlo f
ammonium acetate (100mM, pH4.5), vortexed, loaded onto
0.3 ml Chem Elut extraction cartridge (Varian Sample Prepara-
tion Products, Harbor City, CA, USA), and incubated and eluted
according to the manufacturer’s instructions. The eluents were
dried under a stream of argon. In the second method, sample
extraction was performed as described in [23]. Serum and
hemolymph samples, as described above, were mixed with 1 ml
of water, 50 ml of ethanolic butylated hydroxytoluene (10 mg/ml),
1 ml of 0.1M SDS, and briefly mixed by vortexing. Following the
addition of 2 ml of reagent alcohol (Sigma), the solution was
vortexed for 30 s. Following the addition of 2 ml of hexane,
vortexing for 2 min, and centrifugation for 5 min at 1000 g, the
hexane layer was transferred to a 15 ml tube and dried under a
stream of argon gas. LC-MS/MS analysis of simvastatin and
lovastatin was performed on a LTQ linear ion-trap mass
spectrometer (Thermo Electron, San Jose, CA) coupled with an
Agilent 1200 Series capillary HPLC pump (Agilent Technologies,
Santa Clara, CA) and a Zorbax-SB-C18 column (0.56150 mm,
5 mm in particle size, Agilent Technologies). Isocratic conditions of
65% B were used at a flow rate of 10 mL/min, where the mobile
phases were A: 0.1% formic acid in water, and B: 0.1% formic
acid in acetonitrile. The mass spectrometer was set up to monitor
the fragmentation of the [M+H]+ ions of simvastatin (m/z 419)
and lovastatin (m/z 405). The peak areas found in the selected ion
chromatograms for the m/z 419 R 303 (for simvastatin) and m/z
405 R 303 ( for lovastatin) transitions were used to quantify
simvastatin. The calibration curve was constructed by analyzing a
series of standard solutions comprising of a 5.4 pmol/mlo f
lovastatin and 0, 50, 150, 250, and 500 pmol/ml of simvastatin
under the same LC-MS/MS conditions.
Anoxia/reoxygenation injury resistance
After 2 weeks of feeding either control or simvastatin
supplemented food, a stream of argon was introduced through
an opening in the bottom of 8 ounce plastic fly bottles containing
40 to 50 flies. Excess gas exhausted through the cotton closures at
the top of the bottles. Flies almost immediately became motionless,
and remained so during the 3.5 h of treatment. After the gas was
discontinued, the cotton closure was temporarily removed and air
was reintroduced into the bottle. Survival rates were determined
24 hours later. There were no deaths in the 2 hours immediately
following reoxygenation.
Dietary paraquat resistance
Two methods of determining the sensitivity of flies to dietary
paraquat (a.k.a. Methyl viologen; N,N9-dimethyl-4,49-bipyridi-
nium dichloride). The first used fly bottles containing 4-day-old
male flies incubated as described for lifespan studies with SCM
containing lids spread with 10 ml of DMSO containing 1 or 5 mM
paraquat, with or without 240 mM simvastatin. Control groups
were cultured with SCM disks spread with 10 ml of DMSO or
10 ml of DMSO containing 240 mM simvastatin. The disks were
changed twice weekly. A total of 4 to 8 bottles per treatment
group, with 30–50 male flies per bottle (200 to 240 flies total) were
used for each determination. Survival was assessed every other
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[16,51]. Thirty-five to 45 flies in 8 ounce plastic fly bottles were fed
standard SCM with or without 240 mM of simvastatin for 10 or
20 days. After 2–5 hours without food, Whatman filter paper
wetted with 0.5 ml of 20 mM of paraquat in 5% sucrose was
inserted into each bottle for 7 or 16 h, followed by 48 h under
standard conditions. The number of survivors was determined by
counting. Statistical significance was judged using two-tailed t-
tests, as implemented in GraphPad Prism 5.0.
Statistics
Drosophila survival analysis utilized the log-rank tests as
implemented in SAS. The significance of the effects of simvastatin
on survival after hypoxia-reoxygenation and paraquat stress, and
on the effects of simvastatin on Drosophila heartbeat were
determined using two tailed unpaired t-tests.
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